Quotient Sciences Enhances Manufacturing Partnership for Ultra-Rare Disease Treatment

Quotient Sciences Strengthens Its Commitment to Ultra-Rare Diseases

Quotient Sciences, a prominent integrated Contract Research, Development and Manufacturing Organization (CRDMO), has officially announced the continuation of its commercial supply partnership with Ipsen. This collaboration aims to produce a vital treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease that affects fewer than 1,000 individuals globally. This move emphasizes Quotient Sciences' dedication to supporting the manufacturing of specialized treatments that are often ignored by larger Contract Development and Manufacturing Organizations (CDMOs).

The Significance of the Partnership

Fibrodysplasia Ossificans Progressiva (FOP) is an exceptionally rare genetic condition characterized by the abnormal development of bone in areas where bone typically would not exist. The treatment, known as Sohonos (Palovarotene), was approved by the FDA in 2023. It is a highly potent therapeutic compound that necessitates specialized handling procedures to safeguard both the production environment and the personnel involved in its manufacturing.

The extended partnership with Ipsen underscores a mutual commitment to addressing the profound needs associated with FOP treatment. Ipsen has made significant investments in Quotient Sciences' state-of-the-art facility located in Boothwyn, Pennsylvania, acquiring advanced equipment necessary for the safe and efficient handling of the drug molecule. Noteworthy additions include a Pneumatic Closed Transfer System designed to facilitate safe material transfers while preserving blend integrity, and a Flexible Dispensing Isolator that enhances operator safety and streamlines cleaning protocols.

Advanced Manufacturing Capabilities

Quotient Sciences' facility is strategically equipped to manage the complexities associated with manufacturing highly potent active pharmaceutical ingredients (HPAPIs) and products. With validated occupational exposure limits (OELs) at or below 1 µg/m³, the facility is set to increase its production capacity for medications that tackle rare diseases without compromising safety and efficacy. Moreover, these upgrades enable Quotient Sciences to seamlessly integrate these technological advancements with existing machines, enhancing overall operational efficiency.

Marlene Leuenberger, Vice President and General Manager at Quotient Sciences, expressed the company’s commitment, stating, "This significant investment in advanced containment and manufacturing technology at our Boothwyn facility signifies our unwavering dedication to supporting patients with ultra-rare diseases. By enhancing our capabilities to handle highly potent compounds, we ensure a reliable supply of critical therapies like Sohonos for the FOP community, while also extending high-quality solutions to our partners."

Ensuring a Steady Supply

The renewed partnership is designed to guarantee an uninterrupted commercial supply of the therapy essential for those living with FOP. As there is a growing demand for treatments addressing rare diseases, Quotient Sciences' strategic advancements put the company in a favorable position to meet these emerging needs effectively.

As an integrated CRDMO, Quotient Sciences offers a comprehensive suite of services throughout the drug development process. Their proprietary platform for drug development, known as Translational Pharmaceutics®, has been a cornerstone for clients seeking integrated formulation development and clinical testing solutions for over 17 years. By effectively bridging gaps across various phases of drug development, the organization assists in the crucial task of bringing life-saving therapies to patients faster and more efficiently.

For more information about Quotient Sciences and their groundbreaking work in drug development, please visit their official website at quotientsciences.com.